ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Dongsheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.